MedTrace Logo

A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients

NCT03706690 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 407

Last updated 2026-05-13

Study results available
· View outcomes & findings →

Summary

This is a Phase III, randomised, double-blind, placebo-controlled, multicentre study assessing the efficacy and safety of durvalumab compared with placebo, as consolidation therapy in patients with locally advanced, unresectable, non-small cell lung cancer (Stage III), who have not progressed following definitive, platinum-based, chemoradiation therapy.

Conditions

  • Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

Durvalumab

Durvalumab 1500 mg every 4 weeks \[q4w\] intravenously \[iv\] until clinical progression/ deterioration or confirmed radiological progression.

OTHER

Placebo

Matching placebo for infusion every 4 weeks iv until clinical progression/deterioration or confirmed radiological progression

Sponsors & Collaborators

Principal Investigators

  • Yilong Wu, MD · Guangdong General Hospital, Guangdong Lung Cancer Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
130 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-27
Primary Completion
2024-06-23
Completion
2027-02-26
FDA Drug
Yes

Countries

  • China
  • Hong Kong
  • India
  • Mexico
  • Philippines
  • Poland
  • Russia
  • South Korea
  • Taiwan
  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03706690 on ClinicalTrials.gov